Platinum-resistant ovarian cancer
Clinical trials for Platinum-resistant ovarian cancer explained in plain language.
Never miss a new study
Get alerted when new Platinum-resistant ovarian cancer trials appear
Sign up with your email to follow new studies for Platinum-resistant ovarian cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough ovarian cancer: CBX-12 trial launches
Disease control Stopped earlyThis study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specif…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase 2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Ovarian cancer drug combo trial halted early – what we know
Disease control Stopped earlyThis study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase 1/2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cancer drug trial halted midway: what happened?
Disease control Stopped earlyThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase 2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control Stopped earlyThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase 1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for tough ovarian cancer? trial tests smart drug vs chemo
Disease control Stopped earlyThis study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase 2/3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Ovarian cancer study reveals hidden struggles of patients and caregivers
Knowledge-focused Stopped earlyThis study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal wa…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC